[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [ALTEOGEN Inc.](/topic/$196170kq) ### Top Social Posts *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "🕰 X minutes subcutaneous administration of pembrolizumab every X weeks is a game changer. 💉Berahyaluronidase alfa (MK-5180 Alteogen Inc.) acts as a permeation enhancer that temporarily degrades hyaluronan in the extracellular matrix surrounding the injection area increasing dispersion and enabling subcutaneous administration of pembrolizumab. @EnriquetaFelip brilliantly presented Phase III MK-3475A-D77 trial with simultaneous publication @Annals_Oncology @myESMO #ESMOAmbassadors #ELCC25 #LCSM" [X Link](https://x.com/Tony_Calles/status/1905285069775778172) [@Tony_Calles](/creator/x/Tony_Calles) 2025-03-27T15:45Z 12.1K followers, 6873 engagements "Could ADCs be safely administered subcutaneously - clinical data of a sc ADC (JSKN003) just presented at #SITC2024 with favorable safety - Daiichi entered in a partnership with Alteogen to develop a sc formulation of T-DXd - -" [X Link](https://x.com/PTarantinoMD/status/1856093263175852396) [@PTarantinoMD](/creator/x/PTarantinoMD) 2024-11-11T21:54Z 29.4K followers, 11K engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"🕰 X minutes subcutaneous administration of pembrolizumab every X weeks is a game changer. 💉Berahyaluronidase alfa (MK-5180 Alteogen Inc.) acts as a permeation enhancer that temporarily degrades hyaluronan in the extracellular matrix surrounding the injection area increasing dispersion and enabling subcutaneous administration of pembrolizumab. @EnriquetaFelip brilliantly presented Phase III MK-3475A-D77 trial with simultaneous publication @Annals_Oncology @myESMO #ESMOAmbassadors #ELCC25 #LCSM"
X Link @Tony_Calles 2025-03-27T15:45Z 12.1K followers, 6873 engagements
"Could ADCs be safely administered subcutaneously - clinical data of a sc ADC (JSKN003) just presented at #SITC2024 with favorable safety - Daiichi entered in a partnership with Alteogen to develop a sc formulation of T-DXd - -"
X Link @PTarantinoMD 2024-11-11T21:54Z 29.4K followers, 11K engagements
/topic/$196170kq/posts